Skip to main content
Dechra Pharmaceuticals PLC logo

Dechra Pharmaceuticals PLC — Investor Relations & Filings

Ticker · DPH ISIN · US2434351043 LEI · 213800J4UVB5OWG8VX82 IL Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2014-05-30 Share Issue/Capital Cha…
Country GB United Kingdom
Listing IL DPH

About Dechra Pharmaceuticals PLC

https://www.dechra.com/

Dechra Pharmaceuticals PLC is a global specialist business focused on veterinary pharmaceuticals and related products. The company's expertise encompasses the development, manufacture, marketing, and sale of high-quality veterinary medicines. Its product portfolio includes both novel and differentiated generic pharmaceuticals, with a significant focus on products for companion animals. Dechra provides solutions and support to veterinary professionals worldwide to improve animal health and welfare.

Recent filings

Filing Released Lang Actions
Total Voting Rights
Share Issue/Capital Change Classification · 99% confidence The document is very short (1894 characters) and is explicitly marked with an 'RNS Number'. The content notifies the market about the total number of issued ordinary shares with voting rights (87,708,167) as required by DTR 5.6.1R. This type of mandatory disclosure regarding the total share capital used as a denominator for shareholder notifications is a standard regulatory announcement. Since it is a general regulatory notification that doesn't fit the specific categories like Director's Dealing (DIRS), Share Issue (SHA), or Transaction in Own Shares (POS), the most appropriate classification is the general Regulatory Filings category (RNS).
2014-05-30 English
US portfolio strengthened though acquisition
M&A Activity Classification · 99% confidence The document is identified by the 'RNS Number' header and the closing statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details an acquisition (M&A activity) by Dechra Pharmaceuticals PLC, including financial considerations and product integration. While it describes a significant corporate event, the format is that of a regulatory news service announcement, not a comprehensive report like a 10-K or IR. Since the core event is an acquisition/takeover proposal, the most specific category is M&A Activity (TAR). However, because this is explicitly formatted as an RNS announcement, and RNS is the general regulatory filing category, I must choose between TAR (M&A Activity) and RNS (Regulatory Filings). Given the strong M&A content, TAR is more specific. If TAR were not available, RNS would be the fallback. Since TAR is available and the event is clearly M&A, TAR is the best fit for the *content*, but RNS is the best fit for the *format* if the content was less specific. In this case, the document is a specific announcement of a transaction, which falls under M&A Activity (TAR). If the document were merely announcing the *release* of an M&A document, RPA would apply. Since this *is* the announcement detailing the M&A, TAR is appropriate.
2014-05-20 English
FDA & VMD approvals for equine and US ophthalmics
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and the date '02 May 2014', indicating it is a regulatory announcement disseminated via the Regulatory News Service (RNS). The content details specific business updates, namely 'MARKETING APPROVALS' for veterinary products (Osphos® and Vetropolycin®/Vetropolycin® HC) from the FDA and VMD, and an update on a future submission. This is not a comprehensive annual report (10-K), an interim report (IR), an earnings release (ER), or a management discussion (MDA). It is a specific, material announcement released to the market via the official regulatory channel. Since it is a general regulatory announcement that doesn't fit the more specific categories like DIV, DIRS, or MANG, the most appropriate classification is the general regulatory filing category, RNS.
2014-05-02 English
Trading Update
Earnings Release Classification · 99% confidence The document is identified by the RNS Number header and contains an 'Interim Management Statement' covering the third quarter ended March 31, 2014. This content—a summary of revenue growth, segment performance, and operational updates for a period shorter than a full year—is characteristic of a comprehensive quarterly financial report, which aligns with the definition of an Interim/Quarterly Report (IR). Although it is an update, it provides detailed financial performance metrics for the period, distinguishing it from a mere Earnings Release (ER) which usually contains only highlights, or a Report Publication Announcement (RPA) which only announces the release of a report. The document length (3889 chars) is substantial enough to be the report itself, not just a brief announcement. Q3 2014
2014-04-30 English
Director/PDMR Shareholding
Remuneration Information Classification · 99% confidence The document is very short (1712 chars) and is clearly identified as originating from 'RNS Number' and 'The company news service from the London Stock Exchange'. The content explicitly details the 'Grant of SAYE options' to Directors and PDMRs, including the number of options granted and the exercise price. This directly corresponds to the definition of Director's Dealing (insider transactions/share dealings by executives). Therefore, the appropriate code is DIRS.
2014-04-07 English
Holding(s) in Company
Regulatory Filings Classification · 98% confidence The document is clearly identified by the header 'RNS Number : 9660D' and the closing statement 'This information is provided by RNS The company news service from the London Stock Exchange'. The content details a 'TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES', which reports a change in shareholding that crosses a threshold (5% to 8.08%). This type of mandatory disclosure regarding significant changes in ownership is a specific regulatory filing. While it relates to share ownership (which could sometimes overlap with MRQ), the format and explicit RNS branding strongly point to the general regulatory announcement category, RNS, which serves as the catch-all for such disclosures not covered by more specific financial reports or director dealings.
2014-04-03 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.